Moreover, iron deficiency in response to Rox treatment impaired the iron-dependent ubiquitinated degradation of DAT and resulted in the enhancement of DAT function, which ultimately leads to inhibition of the reward. This evidence concerns the gene SLC6A3 and Iron deficiency anemia.